Analytical Data
-
Gene name
C8orf4
- Application
-
Alternative Names
Thyroid cancer protein 1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9NR00
-
Expression Region
1-106aa
-
Molecular Weight
39.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
C8orf4, also known as the "Cancer/Testis Antigen 4" gene, has gained attention in recent years due to its significant role in various biological processes, including cell proliferation and differentiation. Initially identified in the context of cancer research, C8orf4 is predominantly expressed in testis tissues and is also aberrantly expressed in several malignancies, making it a potential biomarker for cancer diagnosis and therapy. Studies have shown that C8orf4 may play a pivotal role in modulating the tumor microenvironment and influencing immune responses. Its involvement in regulating signaling pathways suggests that C8orf4 could be targeted for therapeutic interventions. Furthermore, the production of recombinant C8orf4 protein allows researchers to explore its structure-function relationships, assess its immunogenicity, and evaluate its potential as a vaccine candidate. Understanding the molecular mechanisms underlying C8orf4's functions could provide insights into tumorigenesis and contribute to the development of novel cancer treatments. As research continues to unravel the complexities surrounding C8orf4, it holds promise not only as a biomarker but also as a potential target for immunotherapy strategies in oncology.
